Search

Your search keyword '"Beglinger, Christoph"' showing total 40 results
Start Over Author "Beglinger, Christoph" Publisher s. karger ag
40 results on '"Beglinger, Christoph"'

18. Preface

Author

Beglinger, Christoph, primary and Goeke, Burkhart, additional

Published
2007
Full Text
View/download PDF

34. Helicobacter pylori and Gastric Erosions

Author

Lehmann, Frank S., primary, Renner, Eberhard L, additional, Meyer-Wyss, Beat, additional, Wilder-Smith, Clive H., additional, Mazzucchelli, Luca, additional, Ruchti, Charles, additional, Drewe, Jürgen, additional, Beglinger, Christoph, additional, and Merk, Hans S., additional

Published
2000
Full Text
View/download PDF

40. Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients.

Author

Kaymak T, Moriconi F, Niess JH, Beglinger C, and Hruz P

Abstract

Background: Many patients with moderate to severe Crohn's disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical questions., Methods: In this retrospective study, we analyzed the treatment outcome in moderate to severe CD patients with a steroid-dependent/refractory disease course started on IFX. Withdrawal of IFX was evaluated in patients with deep remission defined as clinical (Harvey-Bradshaw Index ≤4), biochemical (fecal calprotectin [FC] ≤150 μg/g stool) over a period of 2 years, and endoscopic and histological remission before discontinuation of IFX., Results: After induction with IFX, clinical remission was observed in 45/109 patients (41.3%) and clinical response in 61/109 patients (56.0%). Only 8/109 patients (7.3%) achieved deep remission and therefore could be discontinued from IFX therapy. In 4 of these patients (50%), relapse was observed after discontinuation of IFX treatment. FC decreased in these 8 patients in deep remission from 652 ± 168 μg/g stool (mean ± SE) at baseline to 24.9 ± 8.1 μg/g stool at 14 weeks. When compared to patients in deep remission, FC had decreased significantly less at 14 weeks in patients in clinical remission after induction with IFX ( n = 31; 154 ± 55 μg/g stool; p = 0.01), in patients with clinical response after induction achieving clinical remission during the maintenance phase ( n = 11; 352 ± 67 μg/g stool; p = 0.004), or in patients with chronic active disease course on maintenance therapy ( n = 50; 645 ± 93 μg/g stool; p < 0.001)., Conclusion: A low discontinuation rate was observed for steroid-dependent/refractory moderate to severe CD patients with IFX treatment. As FC showed a more or less pronounced decrease depending on the response to the IFX treatment, monitoring of FC may become a noninvasive tool for tailoring biological therapy in CD patients.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results